Andreas Wolff1, Eduard Shantsila2, Gregory Y H Lip2, Deirdre A Lane2. 1. Division of Family Practice, Chilliwack General Hospital, Chilliwack, British Columbia, Canada. 2. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Abstract
OBJECTIVES: to examine the use of antithrombotic therapy and predictors of stroke and death in very elderly (≥85 years) atrial fibrillation (AF) patients in a general practice cohort from the UK. DESIGN: retrospective, observational cohort study; 12-month follow-up period. SETTING: eleven general practices serving the town of Darlington, England representing a population of 105,000 patients. PATIENTS: two thousand two hundred and fifty-nine patients with a history of AF, 561 (24.8%) aged ≥85 years. MAIN OUTCOME MEASURES: use of antithrombotic therapy by age group and predictors of stroke and death. RESULTS: five hundred and sixty-one (24.8%) AF patients aged ≥85 years (mean (SD) age 89 (4) years; 66% female) identified with a mean CHA2DS2-VASc score of 4.6 (SD 1.4). Thirty-six per cent received oral anticoagulation (OAC) compared with 57% in the 75-84 years age group. Forty-nine per cent of the very elderly received antiplatelet (AP) monotherapy; recorded OAC contraindications and declines were greatest among those aged ≥85 years. Stroke risk was highest among the very elderly (5.2% per annum), despite anticoagulation (3.9%). Multivariate analyses demonstrated an increased risk of stroke with AP monotherapy (odds ratio (OR) 2.45, 95% confidence intervals (CIs) 1.05-5.70) and a significant reduction in all-cause mortality with OAC therapy (OR 0.59, 95% CI 0.36-0.99). CONCLUSION: the majority of very elderly AF patients in general practice do not receive OAC despite their higher stroke risk; almost half received AP monotherapy. AP use independently increased the risk of stroke, signifying that effective stroke prevention requires OAC regardless of age, except where true contraindications exist.
OBJECTIVES: to examine the use of antithrombotic therapy and predictors of stroke and death in very elderly (≥85 years) atrial fibrillation (AF) patients in a general practice cohort from the UK. DESIGN: retrospective, observational cohort study; 12-month follow-up period. SETTING: eleven general practices serving the town of Darlington, England representing a population of 105,000 patients. PATIENTS: two thousand two hundred and fifty-nine patients with a history of AF, 561 (24.8%) aged ≥85 years. MAIN OUTCOME MEASURES: use of antithrombotic therapy by age group and predictors of stroke and death. RESULTS: five hundred and sixty-one (24.8%) AFpatients aged ≥85 years (mean (SD) age 89 (4) years; 66% female) identified with a mean CHA2DS2-VASc score of 4.6 (SD 1.4). Thirty-six per cent received oral anticoagulation (OAC) compared with 57% in the 75-84 years age group. Forty-nine per cent of the very elderly received antiplatelet (AP) monotherapy; recorded OAC contraindications and declines were greatest among those aged ≥85 years. Stroke risk was highest among the very elderly (5.2% per annum), despite anticoagulation (3.9%). Multivariate analyses demonstrated an increased risk of stroke with AP monotherapy (odds ratio (OR) 2.45, 95% confidence intervals (CIs) 1.05-5.70) and a significant reduction in all-cause mortality with OAC therapy (OR 0.59, 95% CI 0.36-0.99). CONCLUSION: the majority of very elderly AFpatients in general practice do not receive OAC despite their higher stroke risk; almost half received AP monotherapy. AP use independently increased the risk of stroke, signifying that effective stroke prevention requires OAC regardless of age, except where true contraindications exist.
Authors: Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Ibrahim Sange Journal: Cureus Date: 2022-04-03
Authors: Alberto Pilotto; Pietro Gallina; Massimiliano Copetti; Andrea Pilotto; Francesco Marcato; Anna M Mello; Matteo Simonato; Giancarlo Logroscino; Alessandro Padovani; Luigi Ferrucci; Francesco Panza Journal: J Am Geriatr Soc Date: 2016-06-13 Impact factor: 5.562
Authors: Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip Journal: Nat Rev Cardiol Date: 2020-10-27 Impact factor: 32.419
Authors: Giuseppe Patti; Markus Lucerna; Ladislav Pecen; Jolanta M Siller-Matula; Ilaria Cavallari; Paulus Kirchhof; Raffaele De Caterina Journal: J Am Heart Assoc Date: 2017-07-23 Impact factor: 5.501